EPISEEK® is a liquid biopsy test offered at Nardella Clinic in partnership with Precision Epigenomics. This innovative test detects circulating tumor DNA (ctDNA)—small fragments of DNA released by tumors into the bloodstream. By analyzing unique DNA methylation markers, EPISEEK provides a powerful tool for detecting cancer through a simple blood draw.
What’s New
On September 1, 2026, Precision Epigenomics announced new clinical validation data for EPISEEK, its Multi-Cancer Early Detection (MCED) blood test. The company reports the data show notably strong sensitivity for detecting cancers at early, more treatable stages — including several cancer types that currently lack standard screening options entirely.
The Headline Numbers
According to the company’s announcement, the data are based on an incidence-adjusted analysis of 380 plasma samples, spanning multiple cancer types and stages, benchmarked against SEER (Surveillance, Epidemiology, and End Results) cancer incidence data. Reported figures include:
- 72% incidence-adjusted sensitivity across all stages for a defined group of aggressive cancers — lung, pancreatic, liver, uterine, esophageal, bladder, oropharyngeal, and stomach cancer.
- 58% observed sensitivity for Stage I–II cancers specifically — the stages where early detection has the greatest potential clinical impact.
- Detection capability spanning over 60 cancer types, including strong reported performance in historically hard-to-detect cancers such as stomach, blood and esophageal cancer.
- A reported 72% sensitivity for brain cancer — notable because the company states other MCED platforms have shown 0% detection for brain cancer in comparable case-control studies.
- An overall specificity of 99.5%, with a 65% positive predictive value (PPV) and 99.5% negative predictive value (NPV).
Company leadership framed the results as a meaningful step toward catching aggressive, historically hard-to-screen cancers earlier.
How EPISEEK Works
EPISEEK screens for epigenomic (DNA methylation) signals associated with cancer from a standard blood draw. Rather than relying on complex genomic sequencing, the platform uses qPCR technology, which the company says enables a roughly one-week turnaround time at a lower cost than comparable tests.
- EPISEEK is not intended to diagnose, treat, or cure disease, and performance claims have not been evaluated by the FDA unless otherwise stated. A “Cancer Signal Not Detected” result does not rule out cancer, and an “Abnormal Methylation Signal Detected” result requires confirmatory diagnostic follow-up.
- Intended use is specific: EPISEEK is positioned for adults 45 and older at elevated cancer risk. It is not recommended for individuals who are pregnant, 21 or younger, or currently undergoing active cancer treatment.
- EPISEEK is used alongside — not as a substitute for — standard guideline-recommended cancer screening exams such as colonoscopy, mammogram, Pap smear, or low-dose CT.
Bottom Line
The newly announced data point to meaningful early-stage sensitivity gains for EPISEEK, particularly for cancer types with few or no existing screening tools. As with any newly announced diagnostic performance data, independent validation and peer-reviewed publication will be the next important markers to watch as this technology moves further into clinical use.
Wondering Whether EPISEEK Is Right for You? We’re Here to Help.
Early detection is one piece of a larger picture. Your age, family history, personal risk factors, and existing screening history all shape whether a multi-cancer blood test like EPISEEK makes sense for you, and how to read a result if you have one. It works alongside your guideline-recommended screening, not in place of it.
Book a consultation with the naturopathic doctors at the Nardella Clinic to review your risk profile, discuss whether EPISEEK fits your situation, and build a proactive plan for early detection and overall wellness.
Related Reading
- Introducing EPISEEK: A New Multi-Cancer Blood Test at Nardella Clinic
- Early-Onset Cancers Are on the Rise in Canada
- Lung Cancer: Early Detection Helps Beat the Odds
Source: Precision Epigenomics press release, September 1, 2026 (precision-epigenomics.com).
